premature coronary artery disease
Conditions
Interventions
premature coronary artery disease group VS. healthy control group:N/A
Sponsors
Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Eligibility
Sex/Gender
All
Age
16 Years to 45 Years
Inclusion criteria
Inclusion criteria: Divided into 2 groups: 1.premature coronary artery disease group: (1) The subjects volunteered to join the study and signed informed consent; (2) Age is older than 16 years, male is less than 40 years old, female is less than 45 years old; (3) Male or non-pregnant woman; (4) Complete case data and coronary angiography results.Comply with CHD diagnostic criteria; 2.Normal healthy control: (1) Age and gender are matched with cases; (2) no history of coronary artery disease, hypertension, diabetes, hyperlipidemia, no clinical symptoms, coronary CT or angiography shows no significant stenosis.
Exclusion criteria
Exclusion criteria: 1.premature coronary artery disease group: Any combination of the following should be excluded: (1) the subject did not sign the informed consent; (2) pregnant or lactating women; (3) participated in other clinical trials within 1 month; (4) patients with the following diseases: familial hyperlipidemia, Kawasaki disease, coronary dissection, muscle bridge, abnormal origin of coronary artery, congenital coronary artery malformation, multiple arteritis, acute pulmonary embolism, myocarditis and cardiomyopathy, acute pericarditis, aortic dissection, congenital heart disease; (5) Severe liver and kidney dysfunction, autoimmune disease, chronic wasting disease, malignant tumor, etc.; (6) any other patients who do not meet the inclusion criteria. 2.Normal healthy control: Any combination of the following should be excluded: (1) the subject did not sign the informed consent; (2) pregnant or lactating women; (3) participated in other clinical trials within 1 month; (4) patients with the following diseases: hypertension, diabetes, coronary heart disease , coronary artery dissection, muscle bridge, abnormal origin of coronary artery, congenital coronary artery malformation, multiple arteritis, acute pulmonary embolism, myocarditis and cardiomyopathy, acute pericarditis, aortic dissection, congenital heart disease; (5) with severe liver Renal dysfunction, autoimmune disease, chronic wasting disease, malignant tumor, etc.; (6) any other patients who do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic biomarkers for serum samples;Genome-wide SNP typing;Major Adverse Cardiovascular Events;Medication information;General clinical data;Coronary angiography results;Blood biochemical examination; | — |
Countries
China
Contacts
Public ContactDu Jie
Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease
Outcome results
None listed